Literature DB >> 15285013

New serum biomarkers for detection of HBV-induced liver cirrhosis using SELDI protein chip technology.

Xiao-Dong Zhu1, Wei-Hua Zhang, Cheng-Lin Li, Yang Xu, Wei-Jiang Liang, Po Tien.   

Abstract

AIM: To find new serum biomarkers for liver cirrhosis (LC) in chronic carriers of hepatitis B virus (HBV).
METHODS: Surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry was used to discover biomarkers for differentiating HBV induced LC from non-cirrhotic cohorts. A training population of 25 patients with HBV-induced LC, 20 patients with HCC, and 25 closely age-matched healthy men, was studied.
RESULTS: Two biomarkers with M(r) 7 772 and 3 933 were detected in sera of non-cirrhotic cohorts, but not in patients with HBV-induced LC. A sensitivity of 80% for all LC patients, a specificity of 81.8% for all non-cirrhotic cohorts and a positive predictive value of 75% for the study population were obtained.
CONCLUSION: These two serum biomarkers for HBV-induced LC might be used for diagnosis and assessment of disease progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15285013      PMCID: PMC4576282          DOI: 10.3748/wjg.v10.i16.2327

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  22 in total

1.  The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification.

Authors:  Haleem J Issaq; Timothy D Veenstra; Thomas P Conrads; Donna Felschow
Journal:  Biochem Biophys Res Commun       Date:  2002-04-05       Impact factor: 3.575

2.  [Diagnostic value of five serum markers for liver fibrosis].

Authors:  R Luo; S Yang; J Xie; Z Zhao; Y He; J Yao
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2001-06

3.  Use of proteomic patterns in serum to identify ovarian cancer.

Authors:  Emanuel F Petricoin; Ali M Ardekani; Ben A Hitt; Peter J Levine; Vincent A Fusaro; Seth M Steinberg; Gordon B Mills; Charles Simone; David A Fishman; Elise C Kohn; Lance A Liotta
Journal:  Lancet       Date:  2002-02-16       Impact factor: 79.321

4.  [Biochemical markers of fibrosis in chronic hepatitis and liver cirrhosis of viral origin].

Authors:  J Kozłowska; T Łoch; J Jabłońska; J Cianciara
Journal:  Przegl Epidemiol       Date:  2001

5.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer.

Authors:  Jinong Li; Zhen Zhang; Jason Rosenzweig; Young Y Wang; Daniel W Chan
Journal:  Clin Chem       Date:  2002-08       Impact factor: 8.327

6.  Hepatocellular carcinoma in Italian patients with cirrhosis.

Authors:  M Colombo; R de Franchis; E Del Ninno; A Sangiovanni; C De Fazio; M Tommasini; M F Donato; A Piva; V Di Carlo; N Dioguardi
Journal:  N Engl J Med       Date:  1991-09-05       Impact factor: 91.245

7.  Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients.

Authors:  Yinsheng Qu; Bao-Ling Adam; Yutaka Yasui; Michael D Ward; Lisa H Cazares; Paul F Schellhammer; Ziding Feng; O John Semmes; George L Wright
Journal:  Clin Chem       Date:  2002-10       Impact factor: 8.327

8.  A preliminary analysis of non-small cell lung cancer biomarkers in serum.

Authors:  Xue-Yuan Xiao; Ying Tang; Xiu-Ping Wei; Da-Cheng He
Journal:  Biomed Environ Sci       Date:  2003-06       Impact factor: 3.118

9.  Clinical significance of serum type-III procollagen aminopropeptide in hepatitis B virus-related liver diseases.

Authors:  T T Chang; H C Lin; S D Lee; Y T Tsai; F Y Lee; F S Jeng; J C Wu; P S Yeh; K J Lo
Journal:  Scand J Gastroenterol       Date:  1989-06       Impact factor: 2.423

10.  Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer.

Authors:  C P Paweletz; B Trock; M Pennanen; T Tsangaris; C Magnant; L A Liotta; E F Petricoin
Journal:  Dis Markers       Date:  2001       Impact factor: 3.434

View more
  7 in total

1.  Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification.

Authors:  Jiefeng Cui; Xiaonan Kang; Zhi Dai; Cheng Huang; Haijun Zhou; Kun Guo; Yan Li; Yu Zhang; Ruixia Sun; Jie Chen; Yang Li; Zhaoyou Tang; Toshimasa Uemura; Yinkun Liu
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-22       Impact factor: 4.553

2.  Screening serum hepatocellular carcinoma-associated proteins by SELDI-based protein spectrum analysis.

Authors:  Jie-Feng Cui; Yin-Kun Liu; Hai-Jun Zhou; Xiao-Nan Kang; Cheng Huang; Yi-Feng He; Zhao-You Tang; Toshimasa Uemura
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

Review 3.  Human body fluid proteome analysis.

Authors:  Shen Hu; Joseph A Loo; David T Wong
Journal:  Proteomics       Date:  2006-12       Impact factor: 3.984

4.  Matrix stiffness-mediated effects on stemness characteristics occurring in HCC cells.

Authors:  Yang You; Qiongdan Zheng; Yinying Dong; Xiaoying Xie; Yaohui Wang; Sifan Wu; Lan Zhang; Yingcong Wang; Tongchun Xue; Zhiming Wang; Rongxin Chen; Yanhong Wang; Jiefeng Cui; Zhenggang Ren
Journal:  Oncotarget       Date:  2016-05-31

Review 5.  Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry.

Authors:  Jose L Luque-Garcia; Thomas A Neubert
Journal:  J Chromatogr A       Date:  2006-12-12       Impact factor: 4.759

6.  Two classifiers based on serum peptide pattern for prediction of HBV-induced liver cirrhosis using MALDI-TOF MS.

Authors:  Yuan Cao; Kun He; Ming Cheng; Hai-Yan Si; He-Lin Zhang; Wei Song; Ai-Ling Li; Cheng-Jin Hu; Na Wang
Journal:  Biomed Res Int       Date:  2013-02-19       Impact factor: 3.411

Review 7.  The current state of proteomics in GI oncology.

Authors:  Ying Lin; William S Dynan; Jeffrey R Lee; Zhao-Hua Zhu; Robert R Schade
Journal:  Dig Dis Sci       Date:  2008-12-23       Impact factor: 3.199

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.